Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors - a Nordic cohort study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Collagens in primary frozen shoulder: expression of collagen mRNA isoforms in the different phases of the disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Comorbidities, pain and fatigue in psoriatic arthritis, psoriasis and healthy controls: a clinical cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVES: To investigate whether TNF inhibitors (TNFi) are associated with increased risk of solid cancer in patients with psoriatic arthritis (PsA).

METHODS: From the Nordic clinical rheumatology registers (CRR) here: SRQ/ARTIS (Sweden), DANBIO (Denmark), NOR-DMARD (Norway), ROB-FIN (Finland) and ICEBIO (Iceland) we identified PsA patients who started a first TNFi 2001-2017 (n = 9655). We identified patients with PsA not treated with biologics from (i) the CRR (n = 14 809) and (ii) the national patient registers (PR, n = 31 350). By linkage to the national cancer registers, we collected information on incident solid cancer overall and for eight cancer types. We used Cox regression to estimate hazard ratio (HR) with 95% CI of cancer (per country and pooled) in TNFi-exposed vs biologics-naïve, adjusting for age, sex, calendar period, comorbidities and disease activity. We also assessed standardized incidence ratios (SIR) in TNFi-exposed PsA vs the general population (GP).

RESULTS: We identified 296 solid cancers among the TNFi-exposed PsA patients (55 850 person-years); the pooled adjusted HR for solid cancer overall was 1.0 (0.9-1.2) for TNFi-exposed vs biologics-naïve PsA from the CRR, and 0.8 (0.7-1.0) vs biologics-naïve PsA from the PRs. There were no significantly increased risks for any of the cancer types under study. The pooled SIR of solid cancer overall in TNFi treated PsA vs GP was 1.0 (0.9-1.1).

CONCLUSION: In this large cohort study from five Nordic countries, we found no increased risk of solid cancer in TNFi-treated PsA patients, neither for solid cancer overall nor for eight common cancer types.

Original languageEnglish
JournalRheumatology (Oxford, England)
Volume60
Issue number8
Pages (from-to)3656-3668
Number of pages13
ISSN1462-0324
DOIs
Publication statusPublished - 2 Aug 2021

    Research areas

  • Adult, Antirheumatic Agents/therapeutic use, Arthritis, Psoriatic/drug therapy, Cohort Studies, Female, Glucocorticoids/therapeutic use, Humans, Male, Methotrexate/therapeutic use, Middle Aged, Neoplasms/epidemiology, Proportional Hazards Models, Registries, Risk Factors, Scandinavian and Nordic Countries/epidemiology, Tumor Necrosis Factor Inhibitors/therapeutic use

ID: 67550112